TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04262466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp
Description: Brenetafusp IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and pembrolizumab
Description: Brenetafusp and pembrolizumab IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and chemotherapy
Description: Brenetafusp and chemotherapy IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and monoclonal antibodies and chemotherapy
Description: Brenetafusp and a monoclonal antibody therapy and chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and tebentafusp
Description: Brenetafusp and tebentafusp IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and bevacizumab
Description: Brenetafusp and bevacizumab IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and kinase inhibitors
Description: Brenetafusp and oral kinase inhibitors
Study: NCT03166852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-training
Description: 5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
Study: NCT00660972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
Study: NCT05176340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Thematic Nursing Care Action Modules (STNC-AM)
Description: The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module.
Study: NCT02141230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alli® 60 mg
Description: Participants purchasing Alli®
Study: NCT01177085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-loss and weight-maintenance diets
Description: Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight-loss and weight-maintenance diets
Description: Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
Study: NCT00598923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 100 mg twice per day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 100 twice per day for 6 days after loading dose of phenytoin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: phenytoin
Description: loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
Study: NCT03360682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 MG
Description: Lamivudine 300 MG/day (48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir 600 MG
Description: Abacavir 600 MG/day (48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir 50 MG/day (48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir 50 MG/day (48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil 245Mg Tablet
Description: Tenofovir 245 MG/day (48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 MG
Description: Emtricitabine 200 MG/day (48 weeks)
Study: NCT02805634

Intervention type: OTHER
Group type: OTHER
Intervention: Nine Hole Test
Description: The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nine Hole Test
Description: The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Triple Stimulation Technique
Description: TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triple Stimulation Technique
Description: TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
Study: NCT02956252

Intervention type: PROCEDURE
Intervention: Spinal anesthesia
Description: Spinal anesthesia was used in patients who underwent LC

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: General anesthesia was used in patients who underwent LC
Study: NCT01047137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Stress Intervention
Description: Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Supportive Therapy
Description: There is no focus on stress intervention.
Study: NCT03899025

Intervention type: RADIATION
Group type: OTHER
Intervention: CT
Description: CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
Study: NCT04322409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: 5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: 5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
Study: NCT04818307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macquarie Injury Management group
Description: Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan Mobilization with Movement
Description: Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
Study: NCT02407860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic treatment
Description: Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual breastfeeding counselling
Description: breastfeeding counselling and support by lactation consultant
Study: NCT03964623

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A (Optical Coherence Tomography)
Description: Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A (Optical Coherence Tomography)
Description: Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A (Optical Coherence Tomography)
Description: Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
Study: NCT01786083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application of Problem Solving Technique
Study: NCT04556513

Intervention type: OTHER
Intervention: Paraclinical examination
Description: Respiratory functional tests

Intervention type: OTHER
Intervention: Clinical Examination
Description: Clinical Examination

Intervention type: OTHER
Intervention: Semi-directive interview
Description: By phone

Intervention type: OTHER
Intervention: quality of life questionnaires
Description: SF36, VSRQ, IESR, HADS
Study: NCT02499783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: subcutaneous injections of adalimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: subcutaneous injections of adalimumab
Study: NCT01453036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 23S rRNA point mutation test of Helicobacter pylori
Description: mutation test group\>\> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group \>\> no intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UBT test & Gastroenterology with biopsy c silver stain
Description: UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UBT test & Gastroenterology with biopsy c silver stain
Description: UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
Study: NCT04164940

Intervention type: OTHER
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention already implemented in daily routine by the individual hospitals.

Intervention type: OTHER
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention already implemented in daily routine by the individual hospitals.
Study: NCT01453036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UBT test & Gastroenterology with biopsy c silver stain
Description: UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
Study: NCT04496908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: amniotomy
Description: Artificially rupturing membranes
Study: NCT04164940

Intervention type: OTHER
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention already implemented in daily routine by the individual hospitals.

Intervention type: OTHER
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention already implemented in daily routine by the individual hospitals.

Intervention type: OTHER
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention already implemented in daily routine by the individual hospitals.

Intervention type: OTHER
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention already implemented in daily routine by the individual hospitals.

Intervention type: OTHER
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention already implemented in daily routine by the individual hospitals.
Study: NCT02405013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir
Description: Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
Study: NCT00100698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human growth hormone
Description: growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneously once a day, 18 months
Study: NCT01086826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT+CDDP/5-FU
Description: RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT+CETUXIMAB
Description: RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INDUCTION CTx(TPF)+(RT+CDDP/5-FU)
Description: INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDUCTION CTx(TPF)+(RT+CETUXIMAB)
Description: INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times.
Study: NCT00516477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: voretigene neparvovec-rzyl
Description: Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: voretigene neparvovec-rzyl
Description: Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: voretigene neparvovec-rzyl
Description: Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
Study: NCT00946413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT plus parent education
Description: The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT alone
Description: The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
Study: NCT02941575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystal Ultra
Description: Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All ceramic
Description: IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
Study: NCT03727958

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung and coronary CT assessment
Description: Subjects will undergo simultaneous coronary arteries and thoracic CT assessment

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary CT assessment
Description: Subjects will undergo coronary arteries CT assessment only
Study: NCT03079817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Meditation
Description: Yoga meditation using motor imagery to perceive movement patterns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Drills
Description: Active balance and proprioception drills
Study: NCT02189915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Study: NCT01620203

Intervention type: OTHER
Intervention: No intervention/treatment is given

Intervention type: OTHER
Intervention: No intervention/treatment is given
Study: NCT02892214

Intervention type: PROCEDURE
Intervention: Pelvic floor physical therapy

Intervention type: DRUG
Intervention: estriol cream (ovestin)

Intervention type: PROCEDURE
Intervention: Low-level-laser therapy
Study: NCT02008916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo secukinumab
Description: Placebo to AIN457 (Secukinumab)